Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myeloid leukemia.
Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantarjian HM. Giles FJ, et al. Among authors: avivi i. Hematology Am Soc Hematol Educ Program. 2002:73-110. doi: 10.1182/asheducation-2002.1.73. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446420 Review.
In Section I, Dr. Armand Keating reviews the role of the hematopoietic microenvironment in the initiation and progression of leukemia. ...In Section II, Drs. Anthony Goldstone and Irit Avivi review the current role of stem cell transplantation as therapy for AML and …
In Section I, Dr. Armand Keating reviews the role of the hematopoietic microenvironment in the initiation and progression of leukemia …
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
Chakrabarti S, Avivi I, Mackinnon S, Ward K, Kottaridis PD, Osman H, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW. Chakrabarti S, et al. Among authors: avivi i. Br J Haematol. 2002 Dec;119(4):1125-32. doi: 10.1046/j.1365-2141.2002.03992.x. Br J Haematol. 2002. PMID: 12472597 Free article.
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.
Dann EJ, Bar-Shalom R, Tamir A, Haim N, Ben-Shachar M, Avivi I, Zuckerman T, Kirschbaum M, Goor O, Libster D, Rowe JM, Epelbaum R. Dann EJ, et al. Among authors: avivi i. Blood. 2007 Feb 1;109(3):905-9. doi: 10.1182/blood-2006-04-019901. Epub 2006 Oct 3. Blood. 2007. PMID: 17018856 Free article. Clinical Trial.
Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, Mufti GJ, Finke J, Schattenberg A, Fanin R, Cornelissen JJ, Vernant JP, Russell N, Beguin Y, Thomson K, Verdonck LF, Kobbe G, Tilly H, Socié G, Sureda A; EBMT Lymphoma Working Party. Avivi I, et al. Br J Haematol. 2009 Dec;147(5):719-28. doi: 10.1111/j.1365-2141.2009.07905.x. Epub 2009 Sep 30. Br J Haematol. 2009. PMID: 19793383 Free article.
Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I, Stroopinsky D, Katz T. Avivi I, et al. Blood Rev. 2013 Sep;27(5):217-23. doi: 10.1016/j.blre.2013.07.002. Epub 2013 Aug 13. Blood Rev. 2013. PMID: 23953071 Review.
Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G. Salar A, et al. Among authors: avivi i. J Clin Oncol. 2014 Jun 10;32(17):1782-91. doi: 10.1200/JCO.2013.52.2631. Epub 2014 May 12. J Clin Oncol. 2014. PMID: 24821885 Clinical Trial.
254 results